1
|
Zhenyang G, Nainong L, Xiaoxiong W, Maihong W, Xiaorui F, Zhao W, Hanyun R, Yuhang L, Xiaofan L, Yamei W, Yao L, Mingzhi Z, Yini W, Daihong L, Yujun D, Liangding H, Wenrong H. Myeloablative Haploidentical Transplant as an Alternative to Matched Sibling Transplant for Peripheral T-Cell Lymphomas. Cell Transplant 2021; 30:963689721999615. [PMID: 33745341 PMCID: PMC7989122 DOI: 10.1177/0963689721999615] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The number of HLA-haploidentical allogeneic hematopoietic stem-cell transplantation (Haplo-HSCT) is increasing. Comparative studies about Haplo-HSCT versus allo-HSCT with HLA-matched sibling donors (MSD-HSCT) have been tried in leukemias and B-cell lymphomas. Few studies were reported in Peripheral T-cell lymphomas (PTCLs). We performed a multicenter retrospective study about 52 patients with PTCLs undergoing Haplo-HSCT (n = 20) or MSD-HSCT (n = 32). All Haplo-HSCT recipients received antithymocyte globulin (ATG) based graft versus host disease (GVHD) prophylaxis. The median follow-up for all survivors was 38 months. The 100-day cumulative incidence of grade II to IV acute GVHD was similar (19% in the MSD-HSCT group versus 28% in the Haplo-HSCT group, P = 0.52). The 2-year cumulative incidence of chronic GVHD (limited and extensive) after Haplo-HSCT (30%) was also similar with that in the MSD-HSCT group (50%, P = 0.15). The 3-year relapse rates (33% vs 27%, P = 0.84) and non-relapse mortality (21% vs 22%, P = 0.78) did not differ between these two groups. There were also no differences in 3-year overall survival (OS) (48% vs 50%, P = 0.78) and progression-free survival (47% vs 51%, P = 0.95) between these two groups. On multivariate analysis, prognostic index for T-cell lymphoma (PIT) score (higher than 1: hazard ratio [HR], 4.0; P = 0.003) and disease status (stable or progression disease before HSCT: HR, 2.8; P = 0.03) were independent variables associated with worse OS. We concluded that ATG-based haplo-HSCT platform could work as an alternative to MSD-HSCT for patients with PTCLs.
Collapse
Affiliation(s)
- Gu Zhenyang
- Department of Hematology, Chinese PLA General Hospital, Beijing, China
| | - Li Nainong
- Department of Hematology, Fujian Institute of Hematology, Fuzhou, China
| | - Wu Xiaoxiong
- Department of Hematology, The Forth Medical Center of PLA General Hospital, Beijing, China
| | - Wang Maihong
- Center of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China
| | - Fu Xiaorui
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Wang Zhao
- Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Ren Hanyun
- Department of Hematology, Peking University First Hospital, Beijing, China
| | - Li Yuhang
- Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China
| | - Li Xiaofan
- Department of Hematology, Fujian Institute of Hematology, Fuzhou, China
| | - Wu Yamei
- Department of Hematology, The Forth Medical Center of PLA General Hospital, Beijing, China
| | - Liu Yao
- Center of Hematology, Xinqiao Hospital, Third Military Medical University, Chongqing, China
| | - Zhang Mingzhi
- Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Wang Yini
- Department of Hematology, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Liu Daihong
- Department of Hematology, Chinese PLA General Hospital, Beijing, China
| | - Dong Yujun
- Department of Hematology, Peking University First Hospital, Beijing, China
| | - Hu Liangding
- Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China
| | - Huang Wenrong
- Department of Hematology, Chinese PLA General Hospital, Beijing, China
| |
Collapse
|